Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 225

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 225
---
 the SEPA. Such sales will be made at prices then prevailing or at prices related to the then-current market price. Such registered broker-dealer may, in some circumstances (for instance, if such registered broker-dealer's involvement is not limited to receiving commission not in excess of the usual and customary distributors' or sellers' commissions), be considered to be an underwriterwithin the meaning of Section 2(a)(11) of the Securities Act.The Selling Shareholder has informed us that each such broker-dealer may receive commissions from the Selling Shareholder for executing such sales for the Selling Shareholder and, if so, such commissions will not exceed customary brokerage commissions.

Brokers, dealers, underwriters, or agents participating in the distribution of our common shares offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Shareholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of common shares sold by the Selling Shareholder may be less than or in excess of customary commissions. Neither we nor the Selling Shareholder can presently estimate the amount of compensation that any agent will receive from any purchasers of the common shares sold by the Selling Shareholder.

<div align='center'>155</div>

We know of no existing arrangements between the SellingShareholderor any other shareholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the common shares offered by this prospectus.

We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement, or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of common shares offered by this prospectus by the SellingShareholder,including with respect to any compensation paid or payable by the SellingShareholderto any brokers, dealers, underwriters, or agents that participate in the distribution of such shares by the SellingShareholder,and any other related information required to be disclosed under the Securities Act.

We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the common shares covered by this prospectus by the SellingShareholder.

As consideration for its irrevocable commitment to purchase our common shares under the SEPA, we have issued to the Selling Shareholder 105,840 of